BRIEF published on 12/16/2024 at 07:05, 1 year 6 months ago Relief Therapeutics Reports Promising Outcomes from PKU GOLIKE Trial Biopharmaceutical Clinical Trial PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/16/2024 at 07:05, 1 year 6 months ago Relief Therapeutics annonce des résultats prometteurs de l'essai GOLIKE sur la PKU Biopharmaceutique Essai Clinique PKU GOLIKE Phénylcétonurie Contrôle Métabolique
PRESS RELEASE published on 12/16/2024 at 07:00, 1 year 6 months ago Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial Relief Therapeutics announces final readout of PKU GOLIKE clinical trial showing superior metabolic control during prolonged fasting in PKU patients. Results aim to promote awareness and adoption of PKU GOLIKE Clinical Trial Relief Therapeutics PKU GOLIKE Phenylketonuria Metabolic Control
BRIEF published on 12/13/2024 at 23:05, 1 year 6 months ago Relief Therapeutics to End SEC Reporting Obligations with Form 15F Filing OTCQB SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F
BRIEF published on 12/13/2024 at 23:05, 1 year 6 months ago Relief Therapeutics va mettre fin à ses obligations de déclaration auprès de la SEC avec le dépôt du formulaire 15F OTCQB Bourse Suisse SIX THÉRAPEUTIQUE DE SECOURS Formulaire 15F Rapports De La SEC
PRESS RELEASE published on 12/13/2024 at 23:00, 1 year 6 months ago Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations Relief Therapeutics announces filing of Form 15F to terminate SEC reporting obligations, maintaining listing on SIX Swiss Exchange and U.S. over-the-counter market SIX Swiss Exchange Relief Therapeutics SEC Reporting Form 15F U.S. OTCQB
BRIEF published on 11/11/2024 at 07:05, 1 year 7 months ago Relief Therapeutics Reports Positive Outcomes in RLF-TD011 Trial for Epidermolysis Bullosa Relief Therapeutics RLF-TD011 Clinical Trial Results Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/11/2024 at 07:05, 1 year 7 months ago Relief Therapeutics rapporte des résultats positifs dans l'essai RLF-TD011 pour l'épidermolyse bulleuse THÉRAPEUTIQUE DE SECOURS RLF-TD011 Résultats Des Essais Cliniques Epidermolyse Bulleuse Diversité Du Microbiome
PRESS RELEASE published on 11/11/2024 at 07:00, 1 year 7 months ago Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa Relief Therapeutics reports positive final results from RLF-TD011 clinical trial for Epidermolysis Bullosa, showing effective wound healing and microbiome diversity improvements Clinical Trial Relief Therapeutics RLF-TD011 Epidermolysis Bullosa Microbiome Diversity
BRIEF published on 11/04/2024 at 07:05, 1 year 7 months ago Relief Therapeutics and Renexxion Consider Reverse Merger Biotechnology Shareholder Value Healthcare Reverse Merger Gastrointestinal Disorders
Published on 06/26/2026 at 14:05, 2 hours 18 minutes ago SouthGobi Announces Voting Results of Annual General Meeting of Shareholders
Published on 06/26/2026 at 14:00, 2 hours 23 minutes ago Dateline Chairman Invests $1.95 million through Options Exercise
Published on 06/26/2026 at 13:00, 3 hours 23 minutes ago Aclara Secures Tax Exemption Approval of Over US$20 Million For Its U.S. Heavy Rare Earth Separation Facility in Louisiana
Published on 06/26/2026 at 12:45, 3 hours 38 minutes ago Northern Dynasty Reports Oral Arguments Held
Published on 06/26/2026 at 15:30, 53 minutes ago JMGO Extends Special Savings Beyond Prime Day with N3 Ultimate at Its Best Price Since Launch
Published on 06/26/2026 at 15:23, 1 hour ago Form 8.3 - The Vanguard Group, Inc.: Spire Healthcare Group plc
Published on 06/26/2026 at 15:22, 1 hour 1 minute ago Form 8.3 - The Vanguard Group, Inc.: Senior plc
Published on 06/26/2026 at 15:21, 1 hour 2 minutes ago Form 8.3 - The Vanguard Group, Inc.: SEGRO plc
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Advancing Women’s Health with Rapid Diagnostics: bioMérieux files a Dual 510(k) /CLIA Waiver application to the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel
Published on 06/26/2026 at 07:00, 9 hours 23 minutes ago Améliorer la santé des femmes grâce au diagnostic rapide : bioMérieux dépose auprès de la FDA une demande combinée d’autorisation 510(k) et de dérogation CLIA pour son test BIOFIRE® SPOTFIRE® Vaginitis Panel
